Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
University of Washington
With
OUTLINE: This is a dose-escalation study of aldesleukin. Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Patients also receive aldesleukin subcutaneously (SC) 5 days per week for 6 weeks; or aldesleukin IV on days 2-6 of pembrolizumab cycles 1 and 2. Pembrolizumab treatment repeats every 3 weeks for 4 cycles per treatment course in the absence of clinical disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up via surveillance scans for every 3 months for up to 1 year or until disease progression.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted